Ost-müük TransCode Therapeutics, Inc. - RNAZ CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | 0.17 | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.025457% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.003235% | ||||||||
Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Eelmine sulgemine* | 4.64 |
Avatud* | 4.58 |
Aastane muutus* | 151.65% |
Päeva ulatus* | 4.08 - 4.58 |
52 nädala ulatus | 4.31-42.00 |
Keskmine maht (10 päeva) | 44.45K |
Keskmine maht (3 kuud) | 943.64K |
Turukapitalisatsioon | 4.16M |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 849.93K |
Tulu | N/A |
EPS | -1.42 |
Dividendid (% kasumist) | N/A |
Beeta | -100.00K |
Järgmine tuluaruande kuupäev | N/A |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|---|---|---|---|---|---|
May 30, 2023 | 4.64 | -0.23 | -4.72% | 4.87 | 4.88 | 4.40 |
May 26, 2023 | 4.86 | -0.16 | -3.19% | 5.02 | 5.02 | 4.84 |
May 25, 2023 | 4.79 | -0.78 | -14.00% | 5.57 | 5.57 | 4.70 |
May 24, 2023 | 5.58 | -0.39 | -6.53% | 5.97 | 5.97 | 5.46 |
May 23, 2023 | 5.99 | 0.79 | 15.19% | 5.20 | 7.47 | 5.19 |
Apr 27, 2023 | 0.39 | -0.02 | -4.88% | 0.41 | 0.42 | 0.39 |
Apr 18, 2023 | 0.39 | 0.01 | 2.63% | 0.38 | 0.39 | 0.38 |
Apr 17, 2023 | 0.38 | 0.00 | 0.00% | 0.38 | 0.38 | 0.38 |
Apr 13, 2023 | 0.38 | -0.01 | -2.56% | 0.39 | 0.40 | 0.38 |
Apr 11, 2023 | 0.38 | 0.00 | 0.00% | 0.38 | 0.38 | 0.38 |
Apr 5, 2023 | 0.39 | 0.00 | 0.00% | 0.39 | 0.46 | 0.38 |
Mar 14, 2023 | 0.38 | 0.01 | 2.70% | 0.37 | 0.38 | 0.37 |
Mar 10, 2023 | 0.38 | -0.01 | -2.56% | 0.39 | 0.40 | 0.38 |
Mar 9, 2023 | 0.40 | -0.01 | -2.44% | 0.41 | 0.41 | 0.40 |
Mar 8, 2023 | 0.41 | 0.01 | 2.50% | 0.40 | 0.42 | 0.40 |
Mar 7, 2023 | 0.41 | -0.01 | -2.38% | 0.42 | 0.42 | 0.41 |
Mar 6, 2023 | 0.43 | -0.01 | -2.27% | 0.44 | 0.44 | 0.41 |
Mar 3, 2023 | 0.44 | 0.00 | 0.00% | 0.44 | 0.45 | 0.43 |
Mar 2, 2023 | 0.45 | -0.03 | -6.25% | 0.48 | 0.48 | 0.43 |
Mar 1, 2023 | 0.49 | 0.02 | 4.26% | 0.47 | 0.51 | 0.47 |
TransCode Therapeutics, Inc. Events
Kellaaeg (UTC) (UTC) | Riik | Sündmus |
---|---|---|
No events scheduled |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Kogutulu | 0 | 0 | 0 | 0 | 0 |
Kogu tegevuskulu | 18.6658 | 6.15114 | 0.7266 | 0.45687 | 0.384 |
Müük/Üldine/admin kulud, kokku | 8.43345 | 3.39717 | 0.44215 | 0.23056 | 0.30146 |
Uuringud ja arendus | 10.2324 | 2.75397 | 0.28446 | 0.22631 | 0.08253 |
Tulud majandustegevusest | -18.6658 | -6.15114 | -0.7266 | -0.45687 | -0.384 |
Intressitulud (kulu), muud tulud, neto | 0.02041 | -0.96141 | -1.60243 | -0.15294 | -0.07192 |
Muud, neto | 1.08044 | 0.27222 | -0.01485 | 0.00258 | 0.00248 |
Netotulu enne makse | -17.565 | -6.8434 | -2.34389 | -0.60721 | -0.45344 |
Netotulu pärast makse | -17.565 | -6.8434 | -2.34389 | -0.60721 | -0.45344 |
Netotulu enne erikulusid | -17.565 | -6.8434 | -2.34389 | -0.60721 | -0.45344 |
Netotulu | -17.565 | -6.8434 | -2.34389 | -0.60721 | -0.45344 |
Arvestatav tulu, v a erikulud | -17.565 | -6.8434 | -2.34389 | -0.60721 | -0.45344 |
Arvestatav tulu, koos erikuludega | -17.565 | -6.8434 | -2.34389 | -0.60721 | -0.45344 |
Jaotamisele kuuluv netotulu | -17.565 | -6.8434 | -2.34389 | -0.60721 | -0.45344 |
Keskmine jaotamisele kuuluv aktsia kohta | 12.9772 | 8.42588 | 8.48508 | 8.48508 | 8.48508 |
Jaotatav EPS, v a erakorralised kulud | -1.35352 | -0.81219 | -0.27624 | -0.07156 | -0.05344 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
Jaotamisele kuuluv normaal-EPS | -1.35352 | -0.81182 | -0.27624 | -0.07156 | -0.05344 |
Gain (Loss) on Sale of Assets | 0 | -0.00308 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Kogutulu | 0 | 0 | 0 | 0 | 0 |
Kogu tegevuskulu | 4.90111 | 5.52746 | 4.95356 | 4.70729 | 3.4775 |
Müük/Üldine/admin kulud, kokku | 2.30976 | 2.84072 | 1.90954 | 2.08727 | 1.59593 |
Uuringud ja arendus | 2.59135 | 2.68674 | 3.04402 | 2.62003 | 1.88158 |
Tulud majandustegevusest | -4.90111 | -5.52746 | -4.95356 | -4.70729 | -3.4775 |
Intressitulud (kulu), muud tulud, neto | 0.00477 | 0.00964 | 0.009 | 0.00133 | 0.00044 |
Muud, neto | 0.07941 | 0.38377 | 0.65495 | 0.03473 | 0.00699 |
Netotulu enne makse | -4.81693 | -5.13406 | -4.28961 | -4.67123 | -3.47007 |
Netotulu pärast makse | -4.81693 | -5.13406 | -4.28961 | -4.67123 | -3.47007 |
Netotulu enne erikulusid | -4.81693 | -5.13406 | -4.28961 | -4.67123 | -3.47007 |
Netotulu | -4.81693 | -5.13406 | -4.28961 | -4.67123 | -3.47007 |
Arvestatav tulu, v a erikulud | -4.81693 | -5.13406 | -4.28961 | -4.67123 | -3.47007 |
Arvestatav tulu, koos erikuludega | -4.81693 | -5.13406 | -4.28961 | -4.67123 | -3.47007 |
Jaotamisele kuuluv netotulu | -4.81693 | -5.13406 | -4.28961 | -4.67123 | -3.47007 |
Keskmine jaotamisele kuuluv aktsia kohta | 14.4004 | 12.9772 | 12.9772 | 12.9772 | 12.9772 |
Jaotatav EPS, v a erakorralised kulud | -0.3345 | -0.39562 | -0.33055 | -0.35996 | -0.2674 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Jaotamisele kuuluv normaal-EPS | -0.3345 | -0.39562 | -0.33055 | -0.35996 | -0.2674 |
Gain (Loss) on Sale of Assets | 0 |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Käibevarad kokku | 7.37941 | 22.7322 | 0.83122 | 0.20447 | 0.21465 |
Raha ja lühiajalised investeeringud | 4.97783 | 20.8259 | 0.82802 | 0.20447 | 0.21298 |
Raha ja ekvivalendid | 4.96842 | 20.8259 | 0.82802 | 0.20447 | 0.21298 |
Prepaid Expenses | 2.04135 | 1.90632 | 0.0032 | 0 | 0.00167 |
Total Assets | 7.58799 | 22.9384 | 1.05537 | 0.20447 | 0.21465 |
Total Current Liabilities | 4.34729 | 2.5341 | 0.40486 | 0.06294 | 0.11768 |
Payable/Accrued | 3.42382 | 2.50357 | 0.36918 | 0.02726 | 0.082 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0 | 0.03053 | 0.03569 | 0.03569 | 0.03569 |
Total Liabilities | 4.34729 | 2.5341 | 4.4636 | 1.31425 | 0.71861 |
Total Long Term Debt | 0 | 0 | 2.08668 | 0.92781 | 0.43622 |
Long Term Debt | 0 | 2.08668 | 0.92781 | 0.43622 | |
Other Liabilities, Total | 0 | 1.97206 | 0.3235 | 0.16472 | |
Total Equity | 3.2407 | 20.4044 | -3.40823 | -1.10978 | -0.50397 |
Common Stock | 0.0013 | 0.00129 | 0.00046 | 0.00046 | 0.00076 |
Additional Paid-In Capital | 31.1096 | 30.7083 | 0.05319 | 0.00774 | 0.00605 |
Retained Earnings (Accumulated Deficit) | -27.8703 | -10.3053 | -3.46188 | -1.11799 | -0.51078 |
Total Liabilities & Shareholders’ Equity | 7.58799 | 22.9384 | 1.05537 | 0.20447 | 0.21465 |
Total Common Shares Outstanding | 12.9772 | 12.9046 | 8.48508 | 8.48508 | 8.48508 |
Other Long Term Assets, Total | 0 | 0.22415 | 0 | ||
Property/Plant/Equipment, Total - Net | 0.20858 | 0.20627 | |||
Cash | 0.00941 | ||||
Laekumata arved, neto | 0.36023 | ||||
Property/Plant/Equipment, Total - Gross | 0.34844 | ||||
Accumulated Depreciation, Total | -0.13986 | ||||
Accrued Expenses | 0.92347 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Käibevarad kokku | 4.34662 | 7.37941 | 11.5699 | 13.9208 | 18.6347 |
Raha ja lühiajalised investeeringud | 1.63207 | 4.97783 | 8.79995 | 13.4478 | 16.862 |
Raha ja ekvivalendid | 1.62266 | 4.96842 | 8.79054 | 13.4384 | 16.8526 |
Prepaid Expenses | 2.71456 | 2.04135 | 2.28206 | 0.43826 | 1.77266 |
Total Assets | 5.59051 | 7.58799 | 12.0156 | 14.1555 | 18.85 |
Property/Plant/Equipment, Total - Net | 0.99623 | 0.20858 | 0.20987 | 0.23467 | 0.21532 |
Other Long Term Assets, Total | 0.24765 | 0.23582 | |||
Total Current Liabilities | 5.44949 | 4.34729 | 3.77138 | 1.72725 | 1.84918 |
Payable/Accrued | 3.63739 | 3.42382 | 3.31376 | 1.14011 | 1.4378 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0 | 0.02354 | 0.02354 | 0.02354 | |
Total Liabilities | 5.8273 | 4.34729 | 3.77138 | 1.72725 | 1.84918 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | |||||
Other Liabilities, Total | 0.37781 | ||||
Total Equity | -0.23679 | 3.2407 | 8.2442 | 12.4282 | 17.0008 |
Common Stock | 0.00158 | 0.0013 | 0.0013 | 0.0013 | 0.0013 |
Additional Paid-In Capital | 32.4488 | 31.1096 | 30.9791 | 30.8735 | 30.7749 |
Retained Earnings (Accumulated Deficit) | -32.6872 | -27.8703 | -22.7362 | -18.4466 | -13.7753 |
Total Liabilities & Shareholders’ Equity | 5.59051 | 7.58799 | 12.0156 | 14.1555 | 18.85 |
Total Common Shares Outstanding | 15.8235 | 12.9772 | 12.9772 | 12.9772 | 12.9772 |
Cash | 0.00941 | 0.00941 | 0.00941 | 0.00941 | 0.00941 |
Property/Plant/Equipment, Total - Gross | 0.36134 | 0.34844 | 0.32023 | 0.32023 | 0.27818 |
Accumulated Depreciation, Total | -0.1695 | -0.13986 | -0.11036 | -0.08555 | -0.06286 |
Accrued Expenses | 1.8121 | 0.92347 | 0.43408 | 0.5636 | 0.38784 |
Laekumata arved, neto | 0 | 0.36023 | 0.48788 | 0.03473 |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Netotulu/algväärtus | -17.565 | -6.8434 | -2.34389 | -0.60721 | -0.45344 |
Raha majandustegevusest | -15.7625 | -5.26689 | -0.49297 | -0.50851 | -0.29957 |
Mittelikviidsed varad | 0.3648 | 1.13219 | 1.54116 | 0.10341 | 0.07027 |
Cash Taxes Paid | 0 | 0 | 0 | 0 | |
Makstud intressid | 0.03712 | 0.01787 | 0 | 0 | 0 |
Muutused tööjõus | 1.33905 | 0.40186 | 0.30976 | -0.0047 | 0.0836 |
Rahavood investeeringutelt | 0.00599 | 25.5166 | 1.11652 | 0.5 | 0.51243 |
Rahavoogudesse investeerimine | 0 | -0.83168 | -0.07348 | 0 | -0.04099 |
Aktsiate emiteerimine (tagasiost), neto | 0.00599 | 26.3482 | 0.00342 | ||
Laenu väljastamine (kustutamine), neto | 0 | 1.19 | 0.5 | 0.55 | |
Rahaline kogumuutus | -15.8574 | 19.9978 | 0.62355 | -0.00851 | 0.21286 |
Raha majandustegevusest | 0.09861 | 0.04247 | |||
Tulu investeeringutelt | -0.10092 | -0.25182 | |||
Kapitalikulutused | -0.10092 | -0.25482 | |||
Muud rahavood investeeringutelt, kokku | 0 | 0.003 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -4.81693 | -17.565 | -12.4309 | -8.1413 | -3.47007 |
Cash From Operating Activities | -4.51355 | -15.7625 | -11.7428 | -7.32076 | -3.94857 |
Cash From Operating Activities | 0.02964 | 0.09861 | 0.0691 | 0.0443 | 0.0216 |
Non-Cash Items | 0.22932 | 0.3648 | 0.25778 | 0.15917 | 0.06057 |
Cash Taxes Paid | 0 | 0 | |||
Changes in Working Capital | 0.04442 | 1.33905 | 0.36124 | 0.61707 | -0.56067 |
Cash From Investing Activities | -0.0129 | -0.10092 | -0.0727 | -0.0727 | -0.03066 |
Capital Expenditures | -0.0129 | -0.10092 | -0.0727 | -0.0727 | -0.03066 |
Cash From Financing Activities | 1.18069 | 0.00599 | -0.21983 | 0.00599 | 0.00599 |
Financing Cash Flow Items | 0 | -0.22582 | 0 | ||
Issuance (Retirement) of Stock, Net | 1.18069 | 0.00599 | 0.00599 | 0.00599 | 0.00599 |
Issuance (Retirement) of Debt, Net | |||||
Net Change in Cash | -3.34576 | -15.8574 | -12.0353 | -7.38748 | -3.97323 |
Other Investing Cash Flow Items, Total | 0 | ||||
Cash Interest Paid | 0.0083 | 0.03712 | 0.02062 | 0.00513 | 0.00443 |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group530K+
Kauplejad
87K+
Igakuiste aktiivsete klientide arv
$46M+
Igakuine investeerimise maht
$31M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
TransCode Therapeutics, Inc. Company profile
Ettevõttest TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. on biofarmatseutiline ettevõte, mis keskendub metastaatiliste haiguste raviks mõeldud ravimite väljatöötamisele ja turustamisele. Ettevõte on välja töötanud modulaarse rauaoksiid-nanoosakestel põhineva nanokandja süsteemi RNA-ravimite toimetamiseks kasvajatesse. Ettevõtte peamine ravikandidaat TTX-MC138 on suunatud mikroRNA-10b (miRNA-10b) vastu, mis on metastaatiliste rakkude elujõulisuse peamine regulaator mitmetes vähivormides, sealhulgas rinna-, kõhunäärme-, munasarja-, käärsoolevähi, glioblastoomide ja teiste vähivormide puhul. Tema prekliinilised programmid hõlmavad kahte soliidtuumoriprogrammi, nagu TTX-siPDL1, mis on programmeeritud surma-ligandi 1 (PD-L1) väike interferentne RNA (siRNA) põhinev modulaator, ja TTX-siLin28b, mis on siRNA-põhine RNA-siduva valgu LIN28B inhibiitor.
Industry: | Biotechnology & Medical Research (NEC) |
6 Liberty Square
#2382
BOSTON
MASSACHUSETTS 02109
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 530,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com